Table 1.

The effect of treatment with pCDR1 on the clinical manifestations of experimental SLE

Immunization and treatment	WBC (mean ± SD)	Proteinuria (mean g/l ± SD)	Mean intensity of immune complex deposits ± SD
16/6 Id	2760  ± 391	1.4  ± 0.9	1.1  ± 0.2
16/6Id + reversed pCDR1	3220  ± 311	1.8  ± 1	0.88  ± 0.2
16/6Id + pCDR1	5950  ± 420*†	0.475  ± 0.35‡§	0.37  ± 0.1¶
pCDR1 only	5750  ± 208	0.225  ± 0.15	0.16  ± 0.1
Normal mice	5340  ± 313	0.18  ± 0.16	0.09  ± 0.09

BALB/c mice were immunized with 16/6Id and concomitantly injected with pCDR1 or reversed pCDR1 100 μg/mouse i.v. once per week for 5 weeks. Mice were followed for 8 months. Results of leukopenia and proteinuria were obtained 7 months after immunization and are representative of 3 experiments and of measurements performed at different time points. Results of immune complex deposits were evaluated as follows: 0 = no lesions or minimal lesions; 1 = moderate lesions; 2 = severe lesions. Kidney analyses were performed at death. 

^*, P < 0.01,  

^‡ and  

^¶, P < 0.03 compared to 16/6Id immunized mice that were not treated.  

^†, P < 0.01 and  

^§, P < 0.03 compared to 16/6Id immunized and reversed pCDR1 treated mice, respectively.